35 results
8-K
CADL
Candel Therapeutics Inc
7 Sep 22
Candel Therapeutics Announces Two Executive Leadership Appointments
8:02am
responsibility at Genzyme Corporation (Nasdaq: GENZ) (acquired by Sanofi S.A.) from April 2000 until June 2011, most recently as Senior Vice President … of Deloitte, serving in various roles of increasing responsibility through Senior Manager. Since October 2017, Mr. Amello has served as a member
8-K
CADL
Candel Therapeutics Inc
12 Jan 24
Departure of Directors or Certain Officers
4:30pm
. Schoch joined the Company in November 2021 and has served in various financial reporting and accounting positions of increasing responsibility. Prior
S-1/A
EX-10.10
ciyd9f9 6mneia
16 Jul 21
IPO registration (amended)
6:07am
S-1
EX-10.10
60o6x ppzsgd9zkh
25 Jun 21
IPO registration
5:28pm
DEF 14A
3d41mep4 9colf2
2 Sep 22
Definitive proxy
8:30am
S-1/A
EX-10.6
scd72
16 Jul 21
IPO registration (amended)
6:07am
S-3
EX-4.9
wkikyp8uhoda pq8
5 Aug 22
Shelf registration
5:08pm
S-1/A
EX-10.1
zg6tybg8pyzotymiu
16 Jul 21
IPO registration (amended)
6:07am
S-3
EX-4.8
eko9entld4d
5 Aug 22
Shelf registration
5:08pm
S-1
EX-10.9
bu4bghao380q
25 Jun 21
IPO registration
5:28pm
S-1/A
EX-10.9
hqaut5eay2zct8mn 2mh
16 Jul 21
IPO registration (amended)
6:07am
S-1/A
mufavqw0 do9pwrgr
16 Jul 21
IPO registration (amended)
6:07am
S-1
pvma5 qqnh
25 Jun 21
IPO registration
5:28pm
424B4
ukldt5ffe3lov6cnao
28 Jul 21
Prospectus supplement with pricing info
4:02pm
DRS/A
3x6w7y wpp8i
31 Mar 21
Draft registration statement (amended)
12:00am